Medicare recipients suffering from obesity must pay out of pocket for weight loss drugs like Wecovy and Zepbound.

US pharma major Eli Lilly (NYSE: LLY) yesterday announced executive leadership transitions that will further enhance the ...

The current volatile situation shouldn't preclude investors from buying stocks. Eli Lilly, Vertex, Meta Platforms, and ...

Ozempic is what's known as a GLP-1, a drug class that's prescribed to manage Type 2 diabetes and is effective for weight loss.

Zepbound growth has outpaced Wegovy in recent months, and sales quadrupled to $2.31 billion in the first three months of this year compared to the same period of 2024, while Mounjaro more than ...

Mounjaro was authorised as a weight-loss treatment ... CVS Health said it would no longer cover its weight-loss therapy Zepbound. The importance of biosimilars only continues to grow, driven ...